Conavi Completes First U.S. OCTIV Placement
Conavi Medical completed the first U.S. placement and clinical cases of its OCTIV imaging system at a New York medical center.
Updated on Nov. 2, 2026 in Heart Disease
Conavi Medical completed the first U.S. commercial placement of its OCTIV imaging system at NewYork-Presbyterian/Columbia University Irving Medical Center, where interventional cardiologist Dr. Megha Prasad performed the first clinical cases. The announcement was made on November 2, 2026.
Why it matters
OCTIV combines two established coronary imaging methods in one catheter, which may give cardiologists co-registered views of coronary arteries during treatment. The first U.S. clinical use in New York City marks an early step toward the system's planned U.S. commercial rollout.
The announcement reports a single U.S. placement at one medical center, with the system holding FDA 510(k) clearance and combining intravascular ultrasound and optical coherence tomography in one catheter. No case volume, patient outcomes, or performance comparisons against existing imaging methods were disclosed.
The players
Conavi Medical
Conavi Medical is a Toronto-based medical technology company that trades on the Toronto Stock Exchange Venture under the ticker CNVI and on the OTCQB under CNVIF.
Dr. Megha Prasad
Dr. Megha Prasad is an interventional cardiologist who performed the first clinical cases with the OCTIV system at NewYork-Presbyterian/Columbia University Irving Medical Center.
The details
OCTIV combines intravascular ultrasound and optical coherence tomography in a single imaging catheter, providing simultaneous, co-registered views of coronary arteries to support assessment of coronary artery disease and guidance of percutaneous coronary intervention. The system is powered by Novasight and was introduced under the commercial name OCTIV.
Timeline
November 2, 2026: Conavi announced the first U.S. OCTIV placement and clinical cases.
Ahead of TCT 2026: Conavi plans a targeted U.S. commercial rollout of OCTIV.
Big Picture
OCTIV builds on intravascular ultrasound and optical coherence tomography, two established imaging methods used separately in coronary procedures, by combining them into one catheter that delivers co-registered views during treatment. Its first U.S. clinical use in New York City places a dual-modality approach into routine cardiac catheterization practice.
Patients with coronary artery disease who undergo catheter-based treatment may eventually be imaged with OCTIV, depending on whether their cardiology team adopts the system. The announcement does not describe changes to treatment options, insurance coverage, or daily care.
The takeaway
Dual-modality coronary imaging combines the depth detail of IVUS with the resolution of OCT in one device, a combination that may help cardiologists plan and guide stent placement. Readers following heart disease care should watch whether early U.S. sites report clinical results as the rollout expands.
What happens next
Conavi plans a targeted U.S. commercial rollout of OCTIV ahead of TCT 2026.
Further reading
Explore more on Heart Disease for context on the coronary conditions this imaging system is used to assess.
